Orion published its Interim Report for January-March 2019 on Thursday, 25 April 2019.
8 Mar 2019 I Marketing authorization application has been submitted to EMA. The rolling submission to the FDA in the U.S. was recently completed and the application has also been submitted in the MHLW in Japan.
6 Feb 2019 I Financial Statement Release for 2018 and related materials now published.
The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.
|4/25/2019||Decision by the Board of Directors to acquire own shares|
|4/25/2019||Orion Group Interim Report January-March 2019|
|4/16/2019||297,000 Orion Corporation A shares converted into B shares|
|3/26/2019||Orion Corporation: Organising meeting of the Board of Directors|
|4/11/2019||Fire at Orion’s manufacturing plant in Turku|
|4/11/2019||Publishing of Orion Corporation's Interim Report for January-March 2019 on 25 April 2019|
|3/27/2019||Invitation to Orion's Capital Markets Day in Helsinki on Wednesday 22 May 2019|
|3/8/2019||Darolutamide submitted for European marketing authorization|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion's key research projects include three ongoing Phase III trials, among others.
Orion Corporation has been included in the globally recognised FTSE4Good Index.